Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P22415

UPID:
USF1_HUMAN

ALTERNATIVE NAMES:
Class B basic helix-loop-helix protein 11; Major late transcription factor 1

ALTERNATIVE UPACC:
P22415; B2RBZ4; Q5SY46; Q7Z5Y1

BACKGROUND:
The protein Upstream stimulatory factor 1, with alternative names such as Class B basic helix-loop-helix protein 11 and Major late transcription factor 1, functions as a transcription factor. It specifically binds to E-boxes within DNA, influencing the expression of genes critical for cellular and viral processes.

THERAPEUTIC SIGNIFICANCE:
Given its association with familial combined hyperlipidemia, a condition leading to premature coronary heart disease, Upstream stimulatory factor 1 presents a promising avenue for drug discovery. Targeting this protein could lead to innovative treatments for managing elevated cholesterol and triglyceride levels.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.